



A REVIEW ON FORMULATION AND DEVELOPMENT OF ANTIFUNGAL NAIL LACQUER

Rohit Yadav¹, Ashish Srivastava², Pranveer Singh³

^{1,2,3} Pranveer Singh Institute of Technology, Kanpur, Uttar Pradesh, India

ARTICLE INFO

Article's History

Received: 11th September, 2022

Accepted: 15th October, 2022

Corresponding Author:

† **Rohit Yadav**

Pranveer Singh Institute of
Technology, Kanpur, Uttar
Pradesh, India

Email:

ry3975776@gmail.com

& ashishs75@gmail.com

ABSTRACT

Onychomycosis is the condition that affects the nail bed the most frequently. There is a possibility that dermatophytes, yeasts, or molds that aren't dermatophytes caused it. Oral communication has traditionally played an Antifungal treatment have been used to try to treat the fungus, even though these treatments can make the fungus worse. It can be accompanied by adverse effects as well as interactions with other medications. Topical treatments offer an alternative mode of administration in order to avoid the systemic effects of oral administration. The focus of recent research has been on the development of topical drugs and development in conjunction with one another, physical and laser treatments are being utilized. Topical agents, which might make it easier for the medication to penetrate the dense nail plate. In the following analysis, detailed below are procedures from each of the following categories: both unconventional and innovative. To determine the efficacy, further studies over longer time periods are required. Patients comply with various treatments, but they are more likely to recover when they comply with Follow all of the recommended preventative measures to keep the disease from returning Protein is the primary component of fingernails and toenails, both of which are essentially modified forms of hair. The nail is made up of various components, such as the nail matrix and the nail. Under the nail, the nail root is the part that is growing. The skin is located directly beneath the nail's proximal end. Eponychium or the stratum corneum is the structure of the skin that is located at the proximal end of the body. Pertaining to both the skin and the paronychia, which would be the fold of the skin that is located on the edge of the nail The term for hyponychium is the junctures between the layers of skin that make up the right hand or toe as well as the tip of the trailing edge of the nail. The nail plate, which is tough whereas the portion that can be seen through, is made of keratin. in addition to the connective tissue that is adhered to the nail bed is the base of the nail. The lunula, which has the shape of a crescent, region of the toenail that is white in color.

KEYWORDS: Onychomycosis, tinea pedis, dermatophyte, toenail, antifungal, Nail lacquer

© www.albertscience.com, All Right Reserved.

How to cite this article?

Rohit Yadav, Ashish Srivastava, Pranveer Singh, A review on formulation and development of antifungal nail lacquer, ASIO Journal of Drug Delivery (ASIO-JDD), 2022, 6(1): 21-28.

1. INTRODUCTION

Onychomycosis is a yeast infection that most frequently affects the nails but has the opportunity to spread to the skin that is directly adjacent to the affected nails. This situation includes dark spots on the enamel surface, thickening of something like the enamel surface, and "signifies. This is the situation, yes. Toenail infections are the most common type of nail infection, accounting for roughly 90% of all cases worldwide. This disease presents a number of challenges to overcome. As a result of its manifestation, affected populations experience

difficulties such as local pain, loss of sensation, and a decrease in quality of life, all of which have the potential to impede social interactions and day-to-day activities. [1,2] Dermatophytes known as Dermatophytes, Trichophyton, Trichophyton mentagrophytes, and Trichophyton spp. Dermatophytes that are responsible for onychomycosis the majority of the time. A fungal infection that attacks the skin that surrounds the feet is a common cause of infection. [3] The word "nail" is the origin of the English word "fungus," which comes from the Greek word "mykes." Therefore, a fungal disease of the nail is what is intended when people talk about having "onychomycosis." [4] Dermatophytes known as

Epidermophyton, Trichophyton rubrum, T. mentagrophytes, and Epidermophyton are the dermatophytes that are responsible for onychomycosis the majority of the time. *Tinea pedis* is a common cause of infection. It is an infectious disease fungal infection that affects the skin all around the feet. In most cases, infectious diseases are caused by fungi. [5]

ETIOLOGY AND PATHOPHYSIOLOGY

Dermatophytes are the most common type of fungus that causes onychomycosis, which is an infection of the nail bed. The terms "ringworm unguis" and "fungal infections" are frequently used interchangeably. Even so, the term "tinea unguis" appears to apply only to situations in which immunocompromised patients are affected by infections caused by skin fungi. Dermatophyte organisms can be geophilic, which means they are found in soil; zoophilic, which means they are found in animals; or hemophilic, which means they are found in humans (anthropophilic). There are three genera that are known to have species that are able to flourish on human skin. Fungal diseases, exospores, and related species are these genera. Because these are organisms that grow fungus, they are able to invade epithelial tissue and soft tissue, including the barrier function, the tresses, and the manicure polish. The most common microbes found in candidiasis appear to be filamentous fungi, which account for roughly 90% of infections, and Epidermophyton, which would have been implicated most broadly in specific instance stability. [1] People who have simultaneous infections of *tinea capitis* (also known as "player's foot"), which are also induced by *T. rubrum*, are more likely to develop onychomycosis of the fingernails. Onychomycosis is a fungal infection of the fingernails. It shouldn't come as much of a surprise that this was discovered. Microcontrollers, *Porum* spp., and the following are both instances of uncommon factors that cause onychomycosis in the U.S. Epidermophyton seems to be the only life form of the genus Division that has been unearthed in human beings. [6]

Figure 1: Species score of Onychomycosis [8]

The fungal infection known as candidiasis can be caught by coming into close contact with pathogens, yeasts, or investment casting that are not dermatophytes. Fungi are able to easily infect the component that has been manicured because it does not have an effective cell-mediated immune system [7]. Fungi contribute to the breakdown of keratin in the nail bed by producing enzymes that have hydrolytic enzymes, keratinolytic, and lipolytic activities, which in turn makes things simpler for fungi to invade the nail [8, 9]. There is a potential that the existence of factors that thus weaken obstacles to ringworm increases the risk of ringworm [8]. This is because ringworm is an infection caused by fungi. Because of the location of the infection and the way in which the fungal infection spreads, onychomycosis can manifest itself clinically in a number of diverse subtypes [9]. These subtypes are used for medical testing. The formation of fungal biofilms not only makes it possible for fungi to circumvent the effects of antifungal treatments that are currently on the market but also contributes to the evolution of anti-fungal resistance [10]. Hotel area rugs, public shower rooms, as well as pool decks are all good places to culture the organisms that are responsible for the outbreak. In the vast majority of instances, an asymptomatic case of dry hyperpigmentation *tinea pedis* comes before onychomycosis. The hyponychial seal can be compromised and broken over time by the dark, warm, and moist environment of footwear as well as by the micro-traumatic pressure that is applied to the nail unit. This makes it possible for the dermatophyte to enter the nail bed. Fingernails are weakened when they are subjected to water on a consistent basis, as is the case in wet work. Dermatophytes are the only types of fungi that can survive without the keratin found in dead corneocytes of the skin, nail polish, and hair. In the foot, dermatophytes produce the result that starts the infection between both the smallest feet, spreads to the hyperpigmented sole, and steadily broadens to the proximal hyponychial interior of micro traumatized nail units. This occurs because the nail units have been micro-traumatized. When the distal finger hyponychium is broken, dermatophytes are able to infect this same nail bed, which then causes the infection to spread proximally as a fair amount of submucosal hyperkeratosis. [11,12] The major site of the infectious disease is the nail bed, which is characterized by a low-grade inflammatory process during the acute phase of the infection and total dystrophic onychomycosis during the chronic phase of the infection of the nail bed. The nail bed is the web host of the infection. The intense lesion of onychomycosis is characterized histologically by spongiosis, acanthosis, parameter to measure with edema, and hyperkeratosis. These symptoms are similar to those seen in psoriasis pathology. A dense inflammation infiltrate develops, as it does in the majority of infections. Candidiasis is a disease that can infect healthy nails.






Figure 2: Risk Factors of Toenail Fingers [13]

EPIDEMIOLOGY AND PREVELANCE

Onychomycosis is a prevalent infection that has been seen more frequently in recent years. *Trichophyton rubrum* was at first thought to be a common contaminant in the United States. However, since the advent of global tourism to Asia, *T. rubrum* has emerged as the most common organism responsible for the disease in the United States. Mycotic toenails make up at least half of all cases of abnormal toenails. Estimates of the prevalence range from 1 percent to 8 percent, and the incidence of the condition is growing. It has been found that health care workers are genetically predisposed to dermatophyte infectious diseases in a hereditary dominant pattern. Aging, diabetes, *tinea cruris*, psoriasis, immune disorders, and living with family and friends who have area for future research are all factors that increase one's risk of developing Onychomycosis[13,14] In people seen by dermatologists, fungal infections are said to be the cause of 23 percent of foot illnesses and 50 percent of nail conditions. Fungal infections, on the other hand, are much less common in humans, affecting only 3% to 5% of the population. [15] The incidence ranges from population to population, which might be because different populations use different screening methods. Thirty-five percent of the 13,695 participants in a large study in Europe who had a variety of foot conditions were found to have a fungal

infection when the samples were microscopically and culturally examined. [16] According to the findings of a single prospective study conducted in Spain on a sample size of one thousand adults older than 20 years, the prevalence of toenail fungus was found to be 2.7%. (Infection is defined as clinically abnormal nails with positive microscopy and culture). [17] A study conducted in Denmark on 5755 adults over the age of 18 indicates that the proportion of fungal toenail infection was 4.0 percent (determined by positive fungal cultures). [18] Over the past couple of years, there may have been an increase in the incidence of mucocutaneous nail infections. This could be the result of an increase in the use of antimicrobial drugs, immunotherapeutic treatment, more sophisticated surgical techniques, or even a rise in the number of people infected with HIV. [19] This, however, was contradicted by a study that was conducted in an outpatient department in Eastern Croatia. This study compared the prevalence of pathogens between two points in time (1986–1988, 47,832 people; 1997–2001, 75,691 people), and it found that the latter period had a higher incidence. [20] It was discovered that the occurrence of fungal infection had greatly increased over the past 10 years, but that the proportion of skin conditions affecting the nails must have decreased by 1 percent (fungal aphthous ulcers overall: 0.26 basis points in 1986–1988 v 0.73 percent in 1997–2001; nail:

10.31 percent in 1986–1988 v 9.31 percent in 1997–2001). This was discovered by comparing the prevalence of ringworm overall to the preponderance of fungal infections affecting the nails.

CLINICAL MANIFESTATION

Fungi are able to infect the nail by entering through the hyponychium and colonizing the underside of both the nail unit plate and the proximal end. Onychomycosis of the dorsal and lateral subungual candidiasis (DLSO) usually affects one or both of the great fingernails and is generally associated with tinea capitis [21]. This condition can also affect the nail beds of the other toes. The nail plate has a yellow-white appearance, is detached as a result of onycholysis, and distal subungual hyperkeratosis is present. On the other hand, a darkening of the onychogenic nail that is brown, black, or orange may be seen less frequently. Dermatophyte is one of the possible presentations of DLSO caused by dermatophytes. Dermatophyte is a suppurative build-up of hyphae and scales that is difficult to treat with antifungal and requires surgical removal of the affected area in addition to systemic medication. Because when the microorganism is the *Melanoides* variation of *Trichophyton mentagrophytes* or other fungi that contain ingredients, such as *Serbia* was performed for dimidiated or *Aspergillus* [22], DLSO might well be associated with black skin pigment of something like the nail (also known as "fungal melanonychia"). Onychomycosis, a fungal disease other than dermatophytes, is frequently accompanied by severe periungual inflammation. Finger eczema (diffuse hyperkeratosis, several or all toenails involved, as well as other skin and nail indications of psoriasis) and trauma-related "is the process" (usually geometrical and subungual dermatitis is missing) are two potential alternative diagnoses for DLSO. Both of these conditions have common characteristics.



Figure 3: Distal and lateral subungual onychomycosis (DLSO): whitish discoloration, onycholysis, and subungual hyperkeratosis. [22]

White Superficial Onychomycosis



Figure 4: White Superficial Onychomycosis [23,24]

Fungi will infiltrate the ventrally manicured plate and form colonies, which will appear as white opaque groupings that can be scraped away. The classic form of fungal infection is caused by *Trichophyton interdigitalis*, in which dermatophytes colonise most of the imaging methods of the enamel surface without penetrating it. However, *Fusarium* spp. as well as other germs may end up causing a white superficial area for further research (WSO), which is categorised by a deeper manicured invasion [23,24].

Proximal Subungual Onychomycosis

A proximal leukonychia will result from the presence of fungal elements, which are typically found in the ventrolateral nail plate. The form of onychomycosis known as anterior submucosal onychomycosis (PSO) that is caused by dermatophytes is extremely uncommon, and in the past, the shape that is caused by *T. rubrum* was thought to be a sign of Human immunodeficiency virus (HIV). It manifests as a white spot in the lunula region, which is located under the anterior nail plate. PSO is a common symptom seen in infected patients with non-dermatophyte moulds, injury induced by *Aspergillus fumigatus* and *Fusarium oxysporum*, and acute periungual inflammatory response is frequently present at the same time. Caused by infection paronychia and pustular psoriatic arthritis of both the nail is both strategies available diagnoses for this condition. [23,24]

Endonyx Onychomycosis

Endonyx onychomycosis is distinguished from other forms of onychomycosis by the presence of humongous nail plate invasion but not nail bed involvement. In terms of its clinical presentation, the affected nail might exhibit membranous dissociation and a milky white darkening. There is no indication of nail bed metaplasia or "is the process" [25], and the nail slab is permanently affixed to the nail bed. This specific infection is exceptionally rare and is brought on by either *T. soudanense* or *Officinalis a. parasiticus*.



Figure 5: End onychomycosis [25]

Total Dystrophic Onychomycosis

Onychomycosis can progress to its most severe stage, known as total dystrophic onychomycosis (TDO), if the DLSO or PSO has been present for a significant amount of time. The inner layer is unevenly thickened and brittle, and it has a yellowish tint.



Figure 6: Total Dystrophic Onychomycosis [26]

DIAGNOSIS

Psoriasis symptoms that appear on the nail include pitting, onycholysis, discoloration, thickening, and irregular ridging. Examine the typical sites for psoriasis to see if there are any plaques (scalp, ears, elbows, knees, and flexures). Onychogryphosis is characterized by hypertrophy and distortion of the nail polish, most commonly occurring on the great toe. This condition is common in people of advanced age. Other possible causes of nail neuropathy in patients with peripheral arterial disease include endophytic opportunity, nail trauma, basal cell carcinoma, malignant tumors, and nail dystrophy engendered by clinical symptoms. This manifests itself initially as a darkening of the nail's proximal end. *Candida albicans* (has been found most commonly in the fingernails of people who frequently submerge their hands in water, and is thus frequently associated with paronychia. [26;27] In the vast majority of cases, samples will be taken from patients at the laboratory. However, in certain circumstances, such as those that occur in rural areas, the doctor may take the samples themselves. It is important to obtain nail clippings and curetting of submucosal debris from the diseased portion of the nail. In order to collect a nail sample and rule out or confirm the presence of superficial white onychomycosis, a blade can be used to scrounge the surface of something like a nail. 1, 2

Because there are typically so few fungi present in a typical specimen, it is in everyone's best interest to provide a significant quantity to the research lab. If you feel it's necessary, you should postpone the independent inquiry so that the nail has time to grow longer. [27, 28] The clinical manifestation of dysplastic nails should alert the health professional to the potential of onychomycosis. However, even though microbes cause only about a portion of all manicured dystrophies (29), any use of suitable diagnostic methods such as microscopic examination and fungal heritage is essential to ensure a correct diagnosis. Needle dystrophies can have either a fungal or a nonfungal underlying cause, and the clinical manifestation of the finger as well as the history of the patient will assist in differentiating between both the two. For instance, diabetes mellitus, advanced age, hyperhidrosis, onychogryphosis, nail trauma, inadequate dilation of blood vessels, and immunosuppression are all risk factors for onychomycosis. Other risk factors include onychogryphosis and onychogryphosis (30). Onychomycosis is likely to present when dystrophic dermatitis, yellow-brown discoloration, and onycholysis are present on the nail. If, indeed, the patient has prior experience of tinea pedis, especially the moccasin type, the evidence supporting this diagnostic test is even bigger and more powerful (31).

Problems with laboratory tests:

Inaccurate negative results and a lag in progress, and the expertise of the laboratory staff is essential to the production of accurate micrographs of specimens. The rate of false negatives can range between 30 and 40%. [32] Mycological culture has been shown to increase sensitivity, but the results may not be available for several weeks due to the slow growth rate of dermatophytes. In order to determine whether or not a civilization plate is negative, it must be incubated for a period of 4 weeks. [33]

TREATMENT

It is believed that multiple factors contribute to unsuccessful treatment with topical and oral antifungals. Long-term clearance is due not only to patient factors like age and health status but also to drug and fungal characteristics. Patient factors involved in long-term clearance are including adherence and polypharmacy. For instance, in a study that evaluated the residue left drug concentration of toenails after cessation of oral therapy, the clippings showed that drug levels persisted for days or weeks just after cessation of treatment response [34]. When looking at treatment trials for fungal vulnerability in ex-vivo versus in-vivo, there is a substantial difference in the outcomes of the two types of research. Antifungal drugs have a tendency to demonstrate somewhat higher good outcomes in ex-vivo experiments, which is something that is customarily not seen when the effectiveness of these drugs is being evaluated in-vivo [35]. The differences in outcomes may be attributable to a number of different factors, such as the drug's bioavailability and penetration, the local actions carried out by keratin, and the behaviours of the fungus in the area of inflammation. According to the findings of one study, the affinity of terbinafine for

keratin reduced both the bioavailability of the medication and its ability to attack bacteria and fungi in the nail bed. [36] It was discovered that the drug was able to be locked away inside the nail plate, which decreased the drug's efficiency in vivo. Notwithstanding the modifications made to the drug formulation to improve its ability to penetrate the nail, the drugs even now appear to have a lower level of effectiveness than was originally expected. Both the patterns of fungal growth within the nail itself and the formation of spores contribute to less successful results in vivo. A high fungal load is engendered inside this affected nail, which further contributes to less-than-ideal treatment outcomes. Additionally, this same slow growth rate of the nails is a contributing factor. The evaluation of the performance of the treatment is based on certain endpoints (Table 1). Other studies, on the other hand, take a more analytical view by needing to rely on mycological or total cures instead of the more subjective clinical cures. In addition, although the big toenail is frequently used as a therapeutic site in a number of studies, others include the other nails as well. This is done so as to determine the percentage of patients who are completely cured. Because the great toenail has lower responsiveness compared to another toenail, the therapeutic responsiveness might look higher when all of the toenails are included. Because of this, it is necessary to take into account the great toenail when determining the effectiveness of a drug. [37] For instance, in the particular instance of oral antifungal medication, the comprehensive cure rates have been reported to be double what when using the wonderful toenail as that of the medicinal reaction site on its own, while the therapeutic options when contemplating the second, third, and fourth fingernails in the same research were 65, 51, and 55 percent, respectively. This was found whenever the medicinal response site was indeed the great toenail.

Table 1: Endpoints for treatment success

Antifungal medications	
Clinical cure	Complete nail clearance* or <10% nail still affected
Mycological cure	Negative culture** and negative microscopy
Complete cure	Clinical cure and mycological cure
Device-based treatment (assessed six months after the first treatment)	
Fingernails	≥12-mm increase in the clear nail, 90mm ² of new clear nail growth (based on the width of the first toenail), or complete clearance if <12mm of the distal nail was involved prior to treatment
Toenails	≥6-mm increase in the clear nail, 60mm ² of new clear nail growth (based on the width of the first toenail), or complete clearance if <6mm of the distal nail was involved prior to treatment

When comparing the results of studies, it is important to keep in mind both the designated endpoints and the target nails that were chosen. In this article, we provide a review of the uses and consequences of new and forthcoming local anesthetic therapies and energy-based equipment for things like the diagnosis of distal subungual onychomycosis. Specifically, we focus on using lasers and light-based therapies

TOPICAL ANTIFUNGAL

When comparing the results of studies, it is important to keep in mind both the designated endpoints and the target nails that were chosen. In this article, we provide an evaluation of the uses and outcomes of new and emerging relevant therapies and power equipment for the treatment of distal submucosal onychomycosis. We focus on using lasers and light-based therapies. In the form of nail polish or solutions, there are a large number of topical treatments available. However, the effectiveness of these treatments is still relatively low. For the diagnosis of onychomycosis, the only topical anti-fungal that has been accepted for use by the U.S. Food and Drug Administration (FDA) of the U.S. is ciclopirox, which has been shown to be effective against both pathogens and yeast. This treatment was only made available in 2014. [38;39] It was hypothesized that perhaps the inability of something like the medication to break through the hard nail plate would be a barrier to its clinical efficacy, which would contribute to the medication's subpar overall performance. [38;39] Numerous studies were conducted for the purpose of determining the level of penetration that ciclopirox is capable of, both with and without the addition of diffusion enhancers. It was demonstrated in one study that ciclopirox managed to reach sufficiently high concentrations inside healthy nails by using an ex-vivo prototype model. This one was particularly true when oil-based permeation enhancers were used. [40;41] This study had some limitations, the most notable of which was the use of healthy nail polish in an ex vivo model. In another study, using ex-vivo approaches of diseased nails to evaluate the fungicidal and fungistatic action of a larger view against *Trichophyton rubrum* (*T. mentagrophytes*) in the appearance of keratin granules, it was found that the drug was not involved. The results of this study showed that ciclopirox was inefficient. [42] In these circumstances, the drug was still not able to kill the pathogenic microbes in almost the same way it was done in the absence of keratin. This suggests that in addition to the best possible infiltration into the nail plate and powerful antimicrobial activity ex vivo, the drug also involves the existence of keratin inside the infected nail in order for it to work within the infected nail. As a result of this, modern cultural anthelmintic therapeutic options strive to achieve better potency by trying to make use of a confluence of things, such as good invasion, new formulations with low surface tension, lower keratin appreciation, and alternate solution mechanisms of action [41]. After this, the potency of these new medicines is frequently evaluated with respect to ciclopirox, which serves as a point of reference. The more recent different antibiotics are outlined in with only an emphasis on one's modes of action and levels of effectiveness.

SURGICAL ANTIFUNGAL TREATMENT

Onychomycosis Treatment via Surgical Procedure In the diagnosis of onychomycosis, surgery is sometimes used as a successful treatment adjuvant. However, since surgery avulsion is both painful and disfiguring, it can only be performed on a single nail or a small number of nails in certain situations. The presence of drug-resistant nondermatophytic fungi, pachyonychia associated with pain, contraindications to the management of oral antifungals, the presence of onychomycosis, and the desire to limit the period of drug therapy and/or lower costs and the occurrence of side effects are all general clear signs for surgical treatment. It may be necessary to combine surgery and chemotherapy, systemic, and/or local anaesthetic treatment in order to achieve the best possible outcomes. Baran as well as Hay allowed us to treat 12 patients with proximal lateral suppurative fungal infection of something like the toenail, which had been caused by a microbe. Prior to the availability of newer antifungal agents, this condition was difficult to treat. These researchers utilized an amalgamation of the surgical avulsion, an oral anti-itch treatment regimen lasting for three months, and topical treatment with only an imidazole in order to prepare. At 12 months, patients with the normal form (NF) had a 50% chance of survival. In another study patients with fingertip onychomycosis caused by *Scytalidium dimidiatum* were successfully treated with surgical nail avulsion, followed by daily application of antimycotic olamine for a period of four months. Twelve months after treatment was discontinued, the onychomycosis was proven to be cured both clinically and mycologically. Avulsion of the nail plate through surgery is an outpatient procedure that only requires local anesthesia. Because it is preferable to consider removing only the infected portion of the nail bed, limited avulsions are almost universally favoured as the reduction method of choice. Because these procedures have the potential to result in the supplementary distal embedding of something like the nail plate, they should both be avoided. Total manicures plate aortic rupture and distal transversal manicures plate Hemi avulsion are two examples. In order to ensure that local anaesthetics and/or nail surgery are safe for the patient, it is essential to collect a preoperative history and conduct a clinical examination. Both of these steps are required. In order to perform surgery, one must first ensure that adequate anesthesia, coagulation factors, and germ-free techniques are in place. A nail elevator is used to detach the nail mattress and needle plate attachments from the enamel surface, as well as to free the nail folds from the nail plate. The disease-ridden nail plate is cut with just an English finger coupler or a heavily loaded nail nipper, and then it is removed with forceps. One such procedure leaves a margin of standard nail around the edge of the diseased nail plate. The local utilization of Monel's solution results in the achievement of blood coagulation. Following surgery, the influenced digit is bandaged, and postoperative treatment is decided to continue until the patient is no longer experiencing pain or drainage. Analgesics are beneficial during the initial few days of treatment. Onycholysis can be managed with something as simple as routine nail trimming. At even the most anterior aspect of the disease-ridden nail plate, the

procedure is carried out with a massive manicure nipper. No anesthesia is administered during the procedure. The most common indications for thinning are primary onychomycosis and secondary candidiasis caused by *Candida* species. However, trimming can also be helpful in the management of onycholysis caused by dermatophytes and nondermatophytic molds. [43,44]

CONCLUSION:

Onychomycosis is a widely accepted fungal infection that has been notoriously difficult to treat up until relatively recently. If treatment is not sought, it could eventually result in the nail plate being destroyed in its entirety. The clinical symptoms of the infectious disease have repercussions on the patient's mental health in addition to their physiological effects. Before beginning systemic treatment for onychomycosis, it is imperative to first gain an approximate diagnosis of the condition. The gold standard for medical testing is the inspection of a specimen by means of the resource usage of a KOH in order to prepare it in conjunction with culture. The treatment consists of multiple modalities, including nail avulsion (either surgically or chemically), as well as topical and systemic therapies. Voriconazole, fluconazole, and terbinafine are all multisystem agents that are currently being administered, and they are doing so very successfully. Itraconazole and terbinafine are two of the more recent antifungals that have been given the go-ahead by the FDA for use in the diagnosis of onychomycosis. Patients may have a better chance of complying with treatment, experiencing more advantageous therapeutic outcomes, and experiencing a lower risk of recurrence as a result of the higher survival rate and shorter treatment courses involved in the new century of antifungal drugs. On August 1, 2010, this entry was published.

REFERENCES:

1. Vlahovic TC. Onychomycosis: evaluation, treatment options, managing recurrence, and patient outcomes. *Clinics in podiatric medicine and surgery*. 2016 Jul 1;33(3):305-18.
2. Lipner SR, Scher RK. Onychomycosis: Treatment and prevention of recurrence. *Journal of the American Academy of Dermatology*. 2019 Apr 1;80(4):853-67.
3. Welsh O, Vera-Cabrera Welsh E. Onychomycosis. *Clinics in dermatology*. 2010 Mar 1;28(2):151-9.
4. Thomas J, Peterson GM, Christenson JK, Kosari S, Baby KE. Antifungal drug use for onychomycosis. *American Journal of Therapeutics*. 2019 May 1; 26(3):388-96.
5. Lecha M., Effendy I., Feuilhade de Chauvin M., Di Chiacchio N., Baran R. Treatment options—development of consensus guidelines. *J. Eur. Acad. Dermatol. Venereol*. 2005; 19:25-33. doi: 10.1111/j.1468-3083.2005.01284. x.
6. Ghannoum MA, Hajjeh RA, Scher R, Konnikov N, Gupta AK, Summerbell R, Sullivan S, Daniel R, Krusinski P, Fleckman P, Rich P. A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. *Journal of the American Academy of Dermatology*. 2000 Oct 1;43(4):641-8.

7. Lipner SR, Scher RK. Onychomycosis: Clinical overview and diagnosis. *Journal of the American Academy of Dermatology*. 2019 Apr 1;80(4):835-51.
8. Goldstein AO, Bhatia N. Onychomycosis: Epidemiology, clinical features, and diagnosis. In: Post TW, ed. *Up to Date*. Waltham, MA. (Accessed on June 30, 2019).
9. Grover C, Khurana A. Onychomycosis: Newer insights in pathogenesis and diagnosis. *Indian J Dermatol Venereol Leprol* 2012; 78(3): 263-70.
10. Gupta AK, Foley KA. Evidence for biofilms in onychomycosis. *G Ital Dermatol Venereol* 2019; 154(1): 50-5.
11. Drago L, Micali G, Papini M, Piraccini BM, Veraldi S. Management of mycoses in daily practice. *G Ital Dermatol Venereol*. 2017 Dec;152(6):642-650.
12. Maddy AJ, Tosti A. Hair and nail diseases in the mature patient. *Clin Dermatol*. 2018 Mar - Apr;36(2):159-166.
13. Arsenijević VA, Denning DW. Estimated Burden of Serious Fungal Diseases in Serbia. *J Fungi (Basel)*. 2018 Jun 25;4(3), 1-5.
14. Heikkilä H., Stubb S. The prevalence of onychomycosis in Finland. *Br. J. Dermatol*. 1995; 133:699-703. doi: 10.1111/j.1365-2133.1995.tb02741.x.
15. Evans EGV. The rationale for combination therapy. *Br J Dermatol* 2001;145(suppl 60):9-13.
16. Roseeuw D. Achilles foot screening project: preliminary results of patients screened by dermatologists. *J Eur Acad Dermatol Venereol* 1999;12(suppl 1): S6-S9.
17. Del Palacio A, Cuetara MS, Garau M, et al. Onychomycosis: a prospective survey of prevalence and etiology in Madrid. *Int J Dermatol* 2006; 45:874-876.
18. Svejgaard EL, Nilsson J. Onychomycosis in Denmark: prevalence of fungal nail infection in general practice. *Mycoses* 2004; 47:131-135.
19. Trepanier EF, Amsden GW. Current issues in onychomycosis. *Ann Pharmacother* 1998; 32:204-214.
20. Barisic-Drusko V, Rucevic I, Biljan D, et al. Epidemiology of dermatomycosis in Eastern Croatia - today and yesterday. *Coll Antropol* 2003; 27(suppl 1):11-17.
21. Pichardo-Geisinger R., Mora D.C., Newman J.C., Arcury T.A., Feldman S.R., Quandt S.A. Comorbidity of tinea pedis and onychomycosis and evaluation of risk factors in Latino immigrant poultry processing and other manual laborers. *South. Med. J.* 2014; 107:374-349. doi: 10.14423/01.SMJ.0000450705.67259.
22. Finch J., Arenas R., Baran R. Fungal melanonychia. *J. Am. Acad. Dermatol.* 2012; 66:830-841. doi: 10.1016/j.jaad.2010.11.018
23. Piraccini B.M., Tosti A. White superficial onychomycosis: Epidemiological, clinical, and pathological study of 79 patients. *Arch. Dermatol.* 2004; 140:696-701. doi: 10.1001/archderm.140.6.696.
24. Piraccini B.M., Lorenzi S., Tosti A. 'Deep' white superficial onychomycosis due to molds. *J. Eur. Acad. Dermatol. Venereol.* 2002; 16:532-533. doi: 10.1046/j.1468-3083.2002.00559.1.x.
25. Tosti A., Baran R., Piraccini B.M., Fanti P.A. "Endonyx" onychomycosis: A new modality of nail invasion by dermatophytes. *Acta Derm. Venereol.* 1999; 79:52-53. doi: 10.1080/000155599750011714.
26. Clinical Knowledge Summaries. Fungal and candidal nail infections. Available from <http://cks.library.nhs.uk/impetigo> (Accessed January 2009).
27. How should fungal nail be treated? *Drug Ther Bull* 2008; 46(1): 3-8.
28. Roberts DT, Taylor WD, Boyle J. Guidelines for treatment of onychomycosis. *Br J Dermatol* 2003; 148: 402-10.
29. Elewski B E, Rinaldi M G, Weitzman I. Diagnosis and treatment of onychomycosis. a clinician's handbook. Califon, N.J: Gardiner-Caldwell SynerMed; 1995.
30. Cohen J L, Scher R K, Pappert A S. The nail and fungus infections. In: Elewski B, editor. *Cutaneous fungal infections*. New York, N.Y: Igaku-Shoin Inc.; 1992. pp. 106-122.
31. Waikato Hospital. Available from http://www.waikatodhb.govt.nz/laboratory/tests/microbiology_tests/mycology_skin_scrapings.htm
32. Olde Hartman TC, van Rijswijk E. Fungal nail infection. *BMJ* 2008; 337:295.
33. Waikato Hospital. Available from http://www.waikatodhb.govt.nz/laboratory/tests/microbiology_tests/mycology_skin_scrapings.htm
34. Lewslie B. Onychomycosis: Pathogenesis, Diagnosis, and Management. *Clin Microbiol Rev.* 1998; 11(3):415-429.
35. Zalacain A, Obrador C, Martinez JP et al. Characterization of the antimicrobial susceptibility of fungi responsible for onychomycosis in Spain. *Med Mycol J.* 2010;49(5):495-499.
36. Ghannoum M, Isham N. Fungal nail infections (onychomycosis): a never-ending story. *PLoS Pathog.* 2014;10(6):e1004105.
37. Shemer A, Sakka N, Baran R, et al. Clinical comparison and complete cure rates of terbinafine efficacy in affected onychomycosis toenails. *J Eur Acad Dermatol Venereol.* 2015;29(3):521-526
38. Queller JN, Bhatia N. The dermatologist's approach to onychomycosis. *J Fungi.* 2015; 1(2):173-184.
39. Del Rosso JQ. The role of topical antifungal therapy for onychomycosis and the emergence of newer agents. *J Clin Aesthet Dermatol.* 2014;7(7):10-18.
40. Bohn M, Kraemer KT. Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis. *J Am Acad Dermatol.* 2000; 43(4 Suppl):57-69.
41. Hafeez F, Hui X, Selner M, et al. Ciclopirox delivery into the human nail plate using novel lipid diffusion enhancers. *Drug Dev Ind Pharm.* 2013; 40(6):838-844.
42. Tachibana H, Kumagai N, Tatsumi Y. Fungicidal activity in the presence of keratin as an important factor contributing to in vivo efficacy: a comparison of efinaconazole, tavaborole, and ciclopirox. *J Fungi (Basel).* 2017;3(4):pii: E58.
43. Baran JR, Hay R. Partial surgical avulsion of the nail in onychomycosis. *Clin Exp Dermatol* 1985; 10:413-8.
44. Rollman O, Johansson S. Hendersonula toruloidea infection: successful response of onychomycosis to nail avulsion and topical ciclopirox olamine. *Acta Derm Venereol (Stock)* 1987; 67:506-10.